To determine treatment strategies and predict the clinical outcome of patients with melanoma it is important to understand the etiology of this disease. Recently, there has been some insight into molecular basis of melanoma including identification of a few of the regulatory factors and genes involved in this disease. For instance, the transcription factor AP-2 plays a tumor suppressor-like role in melanoma progression by regulating genes involved in tumor growth and metastasis. Previously, we have shown that the progression of human melanoma to the metastatic phenotype is associated with loss of AP-2 expression and deregulation of target genes such as MUC18/MCAM, c-KIT, and MMP-2. Increasing evidence demonstrates that the thrombin receptor (proteaseactivated receptor-1, PAR-1) plays a major role in tumor invasion and contributes to the metastatic phenotype of human melanoma. This review focuses on the role of the thrombin receptor in melanoma and its regulation by AP-2. We show that loss of AP-2 expression in metastatic melanoma cells correlates with overexpression of the thrombin receptor. Our analysis of AP-2/Sp1 complexes within the regulatory region of the thrombin receptor demonstrates that AP-2 binds the proximal 3 0 region of the promoter and diminishes PAR-1 expression. Levels of AP-2 and Sp1 proteins in a panel of melanoma cell lines demonstrated a marked decrease in the ratio of AP-2/ Sp1, a decrease that correlated with overexpression of PAR-1 in metastatic melanoma cells. We propose that loss of AP-2 results in increased expression of the thrombin receptor, which subsequently contributes to the metastatic phenotype of melanoma by upregulating the expression of adhesion molecules, proteases, and angiogenic molecules.
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For the purpose of this review, we focused on the expression of the transcription factor AP-2 in melanoma. AP-2, a 52-kDa protein, was first purified from HeLa cells. Partial peptide sequences led to the isolation of the cDNA from a HeLa cell library (Williams et al., 1988) , and the gene was mapped to a region on the short arm of chromosome 6 near the HLA locus (Gaynor et al., 1991) . The AP-2 protein binds to a consensus palindromic sequence, 5 0 -GCCNNNGGC-3 0 , as a homodimer (Bauer et al., 1994; Williams et al., 1988) , although a number of sites that are specifically footprinted by AP-2 have been shown to differ from this consensus sequence (Imagawa et al., 1987) . The DNA-binding domain is located within the C-terminal half of the 52-kDa protein and consists of two putative amphipathic a-helices separated by a 92-amino acid intervening span that is both necessary and sufficient for homodimer formation (Williams and Tjian, 1991) . Buettner et al. (1993) cloned an alternatively spliced AP-2 protein, AP-2B, which differs in its C-terminus and acts as a dominant-negative to AP-2. Transcriptional activity of AP-2 as a positive or negative transcriptional regulator can be seen in its response to different signaltransducing agents. For example, phorbol esters and signals that enhance cAMP levels induce AP-2 activity independently of protein synthesis, whereas retinoic acid treatment of teratocarcinoma cell lines results in a transient induction of AP-2 mRNA levels on the transcription level (Imagawa et al., 1987; Luscher et al., 1989; Buettner et al., 1993) . Other signals demonstrated to stimulate AP-2 expression and activate transcription of target genes include ultraviolet-A radiation and singlet oxygen (Grether-Beck et al., 1996; Huang and Domann, 1998; Gille et al., 2000) .
AP-2 is involved in mediating programmed gene expression during both embryonic morphogenesis and adult cell differentiation. By using in situ hybridization, a restricted spatial and temporal expression pattern has been observed to occur during murine embryogenesis. In particular, regulated AP-2 expression was observed in neural crest-derived cell lineages (from which melanocytes are derived) and in facial and limb bud mesenchyme (Mitchell et al., 1991) . Two recent reports of AP-2-null mutant mice have demonstrated that AP-2 is important for development of the cranial region and for midline fusions. The AP-2-null mice have multiple congenital defects and die at birth (Schorle et al., 1996; Zhang et al., 1996) . The identification of AP-2 target genes involved in development and differentiation remain under investigation. Numerous studies have identified AP-2 target genes that contain functional AP-2-binding elements in the enhancer regions; these include viral genes such as simian virus 40 (SV40) (Lee et al., 1987; Mitchell et al., 1987) , and the human T-cell leukemia virus type I (Nyborg and Dynan, 1990) , and cellular genes, such as those for the murine major histocompatibility complex (H-2 K b ) (Kanno et al., 1989) , human metallothionein-IIa (huMTIIa) (Haslinger and Karin, 1985) , human proenkephalin (Hyman et al., 1989) , and human keratin K14 (Leask et al., 1991) .
AP-2 is a cell type-specific transcription factor expressed in neural crest and ectoderm-derived tissues, including craniofacial, skin, and urogenital tissues (Mitchell et al., 1991; Schorle et al., 1996; Zhang et al., 1996) . AP-2 has been implicated as a critical regulator of gene expression during mammalian development, differentiation, and carcinogenesis (Leask et al., 1991; Schorle et al., 1996; Zhang et al., 1996; Nottoli et al., 1998) . Loss of AP-2 has been implicated in the development and progression of many different types of cancers, including human melanoma, prostate, breast, and colorectal carcinomas. For example, immunofluorescent staining of malignant human prostate tissues indicated that loss of AP-2 expression occurs early in the development of prostate adenocarcinomas (Ruiz et al., 2001) . In clinical specimens of invasive breast cancer, a correlation between low AP-2 expression and disease progression was demonstrated, suggesting a tumor suppressor-like role for AP-2 (Gee et al., 1999) . In colorectal carcinoma, AP-2 expression correlates with p21/WAF1 expression and recurrence-free survival (Ropponen et al., 1999) . These observations indicate that AP-2 plays multiple roles in both normal development and the development/ progression of cancer.
We have previously demonstrated that the transition of melanoma cells from the RGP to VGP is associated with a loss of expression of AP-2 (Bar-Eli, 2001 ). This loss of expression in metastatic melanoma cells resulted in overexpression of the melanoma cell adhesion molecule (MCAM/MUC18) (Jean et al., 1998a) and lack of expression of the tyrosine kinase receptor c-KIT . In addition, inactivation of AP-2 in primary cutaneous melanoma cells (AP-2 positive) by means of a dominant-negative AP-2 gene (AP-2B) led to deregulation of the metalloproteinase MMP-2 gene and increased the cells tumor and metastatic potential in nude mice (Gershenwald et al., 2001) . Furthermore, functional AP-2-binding elements have been identified in other genes involved in the progression of human melanoma such as p21/WAF1 (Zeng et al., 1997) , intercellular adhesion molecule (I-CAM) (Grether-Beck et al., 1996) , c-erbB-2/HER-2/neu (Hollywood and Hurst, 1993; Bosher et al., 1995; Turner et al., 1998) , plasminogen activator inhibitor type I (PAI-1) (Descheemaeker et al., 1992) , insulin-like growth factor binding protein-5 (Duan and Clemmons, 1995) , transforming growth factor-alpha (TGF-a) (Wang et al., 1997) , vascular endothelial growth factor/vascular permeability factor (VEGF/VPF) (Gille et al., 1997 (Gille et al., , 2000 , E-cadherin (Batsche et al., 1998) , hepatocyte growth factor (HGF) , and c-Myc (Gaubatz et al., 1995) . Loss of AP-2 was also observed in clinical specimens of advanced primary and metastatic melanoma, which was associated with malignant transformation and elevated risk of tumor progression (Karjalainen et al., 1998; Baldi et al., 2001) , thus supporting the hypothesis that loss of AP-2 is a crucial event in the progression and metastasis of melanoma. In this review we will summarize our recent data demonstrating an inverse correlation between the expression of AP-2 and the thrombin receptor (PAR-1), which correlates with the malignant phenotype of human melanoma.
Role of the thrombin receptor in melanoma
The thrombin receptor (protease-activated receptor-1, PAR-1) is a unique G-coupled protein receptor that belongs to the protease-activated receptor family. The thrombin receptor is activated when the N-terminus is proteolytically cleaved by the serine protease thrombin, resulting in an irreversible activation of the receptor, thus leading to downstream cell signaling events that evoke a variety of cellular responses (Vu et al., 1991; Grand et al., 1996) . The pathway of cellular activation and induction of mitogenesis by thrombin is well characterized for fibroblasts and other cell types. It involves increases in Ca 2+ and activation of protein kinase C via second messengers, inositol 1,4,5-triphosphate and diacylglycerol (Vouret-Craviari et al., 1992) . Furthermore, activation of the thrombin receptor induces intracellular signaling molecules such as Ras, PAR-1 regulation by AP-2 in human melanoma C Tellez and M Bar-Eli phosphoinositide 3-kinase (PI3 K), and mitogen-activated protein kinase (MAPK), which have been shown to be involved in cell growth, tumor promotion, and carcinogenesis (Grand et al., 1996; Macfarlane et al., 2001) .
The thrombin receptor has recently been implicated to play a central role in tumorigenesis and metastasis (Even-Ram et al., 1998; Nierodzik et al., 1998; Henrikson et al., 1999) . Expression of the thrombin receptor has been detected in human carcinoma cell lines including colon adenocarcinoma (Wojtukiewicz et al., 1995) , laryngeal (Kaufmann et al., 1997) , breast (EvenRam et al., 1998; Henrikson et al., 1999) , pancreatic (Rudroff et al., 1998) , and oral squamous cell carcinoma (Liu et al., 2001) . We have demonstrated that the metastatic melanoma cells A375SM and WM266-4 overexpress the thrombin receptor (Figure 1) . A panel of melanoma cell lines was surveyed by RNase protection assay for a correlation between the level of PAR-1 expression and their metastatic potential. The cell lines included primary and metastatic human melanoma cells with different tumorigenicities and metastatic potentials in nude mice . As shown in Figure 1 , high levels of PAR-1 mRNA were found in the highly metastatic melanoma cells A375SM and WM266-4 (lanes 1 and 2) as opposed to low levels in the nonmetastatic melanoma cells MeWo and SB2 (lanes 7 and 8). The expression of the thrombin receptor was significantly lower in cells transfected with the fulllength AP-2 gene construct, WM266-4-AP-2-transfected cell lines C8, C12, and C12A (Figure 1, lanes 4, 5, and  6) . Furthermore, the thrombin receptor was reported to be a rate-limiting factor in thrombin-enhanced experimental pulmonary metastasis in a murine melanoma cell line, demonstrating a potential role for the thrombin receptor in the metastasis of melanoma (Nierodzik et al., 1998) . In human melanoma cells, thrombin acts as a growth factor, suggesting that signaling by the thrombin receptor is involved in the biological response of these cells, which likely involves downstream regulation of gene products contributing to their metastatic phenotype (Wojtukiewicz et al., 1992; Fischer et al., 1995; Nierodzik et al., 1998) .
Regulation of PAR-1 expression by AP-2
Despite the extensive amount of data elucidating the cellular activation mechanisms mediated by the thrombin receptor, little is known about the regulatory mechanism of this receptor. The regulatory region of the thrombin receptor gene has been cloned, and DNA sequence analysis indicates the presence of many transcription factor-binding elements, including two AP-2/Sp1 complexes at the proximal 3 0 region of the promoter (Figure 2) (Li et al., 1996; Schmidt et al., 1996) . Overall, these complexes contain four putative AP-2-binding elements and seven Sp1-binding elements. We found that the regulatory region of the thrombin receptor shares remarkable similarities with other AP-2 target genes, such as a G+C-rich sequence, lack of conventional TATA and CAAT sequences, and multiple AP-2-binding elements, which makes it a candidate for regulation by the transcription factor AP-2. Our results suggest that loss of AP-2 results in an increase in the expression of the thrombin receptor in metastatic melanoma cells. As shown in Figure 1 , PAR-1 expression was significantly higher in metastatic melanoma 
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C Tellez and M Bar-Eli cells, which have undetectable levels of endogenous AP-2. In contrast, PAR-1 mRNA levels were decreased in nonmetastatic melanoma cells, which express abundant AP-2 protein. This inverse correlation between the expression of AP-2 and expression of PAR-1 coincides with the malignant phenotype of human melanoma. While AP-2 generally serves as an activator of target gene expression, it has been shown to regulate negatively the transcription of several genes, including K3 keratin (Chen et al., 1997) , acetylcholinesterase (Getman et al., 1995) , C/EBPa (Jiang and Lane, 2000) , and manganese superoxide dismutase (Yeh et al., 1998; Zhu et al., 2001) . In all of these studies, it was proposed that AP-2 functions as a repressor by inhibiting or competing with a transcriptional activator (likely Sp1) that has a binding motif that overlaps or is adjacent to the AP-2-binding site. Several lines of evidence indicate that AP-2 represses Sp1-dependent promoters through transcriptional steric interference with the general transcription machinery (Chen et al., 1997) . We have demonstrated a marked decrease in AP-2 expression and DNA-binding activity in metastatic melanoma cells Jean et al., 1998a) . Furthermore, metastatic melanoma cells A375SM and WM266-4 had a ratio of AP-2/Sp1 approximately equal to 1 and expressed high levels of PAR-1 (Figure 3, lanes 1 and 2) . In contrast, the nonmetastatic melanoma cells MeWo and SB2, which expressed minimal levels of PAR-1, had a ratio of AP-2/Sp1 greater than 1 (lanes 6 and 7). Cells transfected with the full-length AP-2 gene, AP-2-C8 and -C12A, displayed an increase in the ratio of AP-2/ Sp1 (lanes 4 and 5) that coincided with the decrease in PAR-1 expression. We concluded that the loss of AP-2 in melanoma cells significantly decreases the ratio of AP-2 to Sp1 and correlates with their metastatic potential. A severe decrease in the ratio of AP-2 to Sp1 expression coincides with the high level of PAR-1 expression in these cells. Furthermore, re-expression of AP-2 restores the AP-2 to Sp1 ratio in melanoma cells and results in downregulation of the thrombin receptor. Thus, our results suggest that AP-2 likely suppresses PAR-1 expression while Sp1 activates it in human melanoma cells.
To determine if AP-2 and Sp1 were involved in the regulation of the thrombin receptor gene, the interaction of AP-2 and Sp1 with the promoter was assessed by the chromatin immunoprecipitation assay (Figure 4) . Chromatin fragments from cultured cells were immunoprecipitated with an antibody to either AP-2 or Sp1, and DNA from the immunoprecipitates was isolated. From this DNA, a 276-bp fragment of the PAR-1 promoter region was amplified by PCR. This region of the promoter contains two AP-2/Sp1 complexes with overlapping binding motifs for these transcription factors PAR-1 regulation by AP-2 in human melanoma C Tellez and M Bar-Eli (see Figure 2) . In melanoma cells that do not express AP-2 (WM266-4), Sp1 was predominantly bound to the PAR-1 promoter (Figure 4) . In contrast, in cells expressing AP-2 (WM266-4-AP-2-transfectant C8), ninefold more AP-2 was bound to the same region of the promoter (Figure 4) . We conclude that both AP-2 and Sp1 are capable of binding the 3 0 regulatory region of the PAR-1 promoter and that binding of AP-2 interferes with the binding of Sp1 to the promoter. Figure 5 is a schematic illustration demonstrating the role of AP-2 and Sp1 in PAR-1 gene expression. Collectively, our studies support the notion that a decrease in the ratio of AP-2/Sp1 in metastatic melanoma cells contributes to overexpression of the thrombin receptor, thus enhancing the metastatic phenotype of these cells.
How activation of PAR-1 contributes to melanoma metastasis
Thrombin is a tightly regulated serine protease that plays a critical role in blood coagulation by activating coagulation factors and initiating cellular responses mediated through the thrombin receptor (Degen and Sun, 1998) . Recent studies indicated that activation of blood coagulation factors is a common occurrence in cancer patients, and these factors have been implicated to contribute to tumor growth (Ornstein and Zacharski, 2001) . The vast majority of cancer patients with metastatic disease have clinical signs of coagulation abnormalities reflecting augmented thrombin generation (Wojtukiewicz et al., 1993) . For example, melanoma is one of a number of human tumor types in which the tumor is associated with an intact coagulation pathway, leading to thrombin generation and conversion of fibrinogen to fibrin in situ immediately adjacent to viable tumor cells (Ornstein and Zacharski, 2001) . In melanoma cancer patients, activated thrombin sources include systemic activation of blood coagulation factors in the circulation as well as locally at the tumor site (Wojtukiewicz et al., 1990; Zacharski et al., 1995; Ornstein and Zacharski, 2001) . Most tumors are likely capable of generating thrombin, presumably via activation of plasma coagulation factor X, by constitutively expressed tissue factor and/or a tumor-associated cysteine protease (Nierodzik et al., 1998) . Several studies have demonstrated that malignant melanoma cells express tissue factor and activate thrombin independently of the blood coagulation pathway, thereby promoting melanoma metastasis (Mueller et al., 1992; Bromberg et al., 1995; Fischer et al., 1995) . In addition, fibrin deposits around the tumor cells may serve as an additional source of thrombin. The deposition of fibrin, which occurs when fibrinogen is cleaved at thrombinspecific cleavage sites, in the stromal tissue surrounding viable tumor cells may store active thrombin that is not accessible to thrombin inhibitors (Weitz et al., 1990) . Thus, active thrombin is released from fibrin clots undergoing degradation by plasmin (Liu et al., 1979) . Therefore, tumor cells that overexpress the thrombin receptor may require subclotting concentrations of thrombin to induce a response in these cells, thus prolonging stimulation of the receptor and transduction of tumor-promoting signals (Fenton, 1988) .
Angiogenesis is a major factor in tumor growth and metastasis of melanoma. Tumors are limited in size by oxygen and nutrient diffusion from nearby vessels. Hence, solid tumors cannot exceed a diameter of 2 mm without the innermost cells undergoing necrosis (Folkman, 1971) . In order for the cells to survive and continue to proliferate, they need an ingrowth of new blood vessels. The process of angiogenesis is mediated by molecules such as vascular endothelial growth factor (VEGF/VPF), basic fibroblast growth factor (bFGF), interleukin-8 (IL-8), type IV collagenase (MMP-2), and platelet-derived growth factor (PDGF). These factors have been shown to be upregulated in tumors and are Figure 5 Schematic of the proposed mechanism for PAR-1 promoter regulation by the transcriptional regulators AP-2 and Sp1. We hypothesize that the low levels of AP-2 expressed in malignant melanoma cells enables Sp1 to bind its motif in the PAR-1 promoter, resulting in activation of the gene. AP-2-positive nonmetastatic melanoma cells or restoration of AP-2 expression in metastatic melanoma cells results in AP-2 binding its elements in the promoter and suppressing PAR-1 gene expression. We conclude that loss of AP-2 expression in human malignant melanoma results in overexpression of PAR-1 PAR-1 regulation by AP-2 in human melanoma C Tellez and M Bar-Eli important mediators of angiogenesis (Carmeliet and Jain, 2000; Kerbel, 2000) . Overexpression of the thrombin receptor by tumor cells can contribute to cell invasion and angiogenesis via activation of the receptor (Richard et al., 2001) . Activation of the thrombin receptor in a variety of cell types can elicit a range of cellular responses and expression of thrombin-responsive genes. Many of the gene products are precisely those that would be required for angiogenesis and tumor invasion, including IL-8 (Ueno et al., 1996) , VEGF , bFGF (Cucina et al., 1999) , PDGF (Shimizu et al., 2000) , MMP-2 (Zucker et al., 1995) , uPA (Yoshida et al., 1994) alpha IIb beta 3, alpha v beta 3, and alpha v beta 5 integrins (Wojtukiewicz et al., 1992; Senger et al., 1996; Even-Ram et al., 2001) . This suggests that activation of the thrombin receptor may facilitate tumor invasion and metastasis through the induction of cell adhesion molecules, matrix-degrading proteases, and stimulating the secretion of angiogenic factors, thus contributing to the metastatic phenotype of melanoma. Taken together, these observations point to a strong link between thrombin, its receptor, PAR-1, and the invasive properties of malignant melanoma. Figure 6 summarizes our view of how activation of the thrombin receptor contributes to the acquisition of the metastatic phenotype in human melanoma.
The blood coagulation mechanism regulates the growth and dissemination of malignancy by multiple mechanisms. It was therefore postulated that anticoagulant drugs may inhibit the progression of certain cancers. Indeed, drugs that block the activity of thrombin such as sulfo-hirudin showed a successful and significant reduction of experimental metastasis in a murine melanoma model (Esumi et al., 1991) . In addition, anticoagulant drugs warfarin and/or heparin were used in animal tumor models with positive results (Ornstein and Zacharski, 1999) . Controlled clinical trials using these drugs were initiated and have produced encouraging outcomes, warfarin and heparin both prolonged the length of survival of patients with small cell carcinoma of the lung and malignant melanoma (Lebeau et al., 1994; Thornes et al., 1994) . These findings suggest a potential role for thrombin inhibitors in cancer therapy. For this reason, several low-molecular weight thrombin inhibitors are under development, which offer a novel treatment strategy for coagulation therapies (Tapparelli et al., 1993; Lombardi et al., 1999) . It remains to be seen if these inhibitors will be useful as antiangiogenic agents in cancer and other diseases where thrombin may be involved, such as chronic inflammation and neurodegenerative diseases. 
Concluding remarks
Our data established a strong link between the coagulation system and malignant melanoma. We provide evidence that loss of AP-2 results in upregulation of the thrombin receptor, which in turn contributes to the acquisition of the malignant phenotype in human melanoma. These data add further weight to the notion that loss of AP-2 is a crucial event in the progression of human melanoma. Loss of AP-2 expression results in deregulation of target genes that become involved in tumor progression and metastasis of melanoma such as MUC18, c-KIT, MMP-2, E-cadherin, p21/WAF-1, VEGF, TGF-a, and HGF. Furthermore, we have identified the thrombin receptor as an AP-2 target gene that plays an active role in tumor progression. Activation of PAR-1 by thrombin within the microenvironment of the tumor can modulate the expression of genes involved in invasion and metastasis, which suggest that both AP-2 and PAR-1 are potential targets for antitumor and antimetastasis therapy.
